Back to search
FDAFDA · Food and drugs·Recall number D-0849-2022

Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net Wt. 30 gram tube, Rx Only, Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141 Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, NDC 63739-054-66

Published May 11, 2022 · Recall initiated: April 21, 2022

Summary

FDA records drug Class II recall D-0849-2022, published May 11, 2022 and initiated April 21, 2022. Recalling firm: McKesson Corporation dba McKesson Drug Company; Status: Ongoing; Reported quantity: 1176 tubes; Lot: Lot: 16876, Exp.: 05/31/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
McKesson Corporation dba McKesson Drug Company
Distributor
Nationwide in the United States including Guam and the Northern Mariana Islands.
Lot
Lot: 16876, Exp.: 05/31/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net Wt. 30 gram tube, Rx Only, Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141 Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, NDC 63739-054-66 recalled?

Yes. FDA published recall D-0849-2022 on May 11, 2022. Reported hazard: CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

What should I do if I have this product?

Voluntary: Firm initiated · Letter